CHICAGO (GenomeWeb) – The National Cancer Institute's Molecular Analysis for Therapy Choice (MATCH) trial, which officially launches today, is set to begin enrolling patients from sites across the US this July.

Representatives from NCI and Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group provided new details on the effort — a phase II trial aimed at testing targeted therapies against specific tumor alterations across tumor types — at the American Society of Clinical Oncology annual meeting this morning.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.

May
04
Sponsored by
Qiagen

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

May
11
Sponsored by
PerkinElmer

This webinar will provide an overview of an RNA-seq protocol that has been optimized to study small RNA species such as microRNAs.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants. 

Jun
20
Sponsored by
OmniSeq

This webinar will discuss RNA sequencing as an alternative to immunohistochemistry (IHC) in selecting patients for cancer immunotherapy.